))
Highlights from ASH 2024, Leukemia Edition (Continued)
Manage episode 456624058 series 3560283
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition with a focus on leukemia, as well as Healio’s top headlines from the meeting.
Aaron T. Gerds, MD, MS, discusses how socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia. :24
Hua Zhang, MD, PhD, reviews findings of bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia. 6:29
Moath Albliwi, MD, discusses the results of a study he co-presented examining treatment of elderly patients with acute myeloid leukemia. 00:00
Alexey Danilov, MD, PhD, reviews the efficacy of epcoritamab among heavily pretreated patients with advanced chronic lymphocytic leukemia. 00:00
Lee Greenberger, PhD, discusses results of the AMPLIFY study. 16:30
Read the full coverage here:
Socioeconomic factors a barrier to HSCT for people with acute myeloid leukemia
Bicistronic CAR-T effective for children with relapsed B-ALL
VIDEO: Study probes treatment of elderly patients with acute myeloid leukemia
First-line regimen improves PFS in chronic lymphocytic leukemia
Epcoritamab exhibits ‘very encouraging’ efficacy in heavily pretreated CLL
Addition of blinatumomab to chemotherapy improves outcomes for children with B-cell ALL
Disclosures:
Albliwi reports no relevant financial disclosures.
Danilov reports research funding from and/or consulting roles with AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Genmab, Incyte, Janssen and other companies. Please see the abstract for all other researchers’ relevant financial disclosures.
Gerds reports consulting roles with AbbVie, Bristol Myers Squibb, Disc Medicine, GSK, PharmaEssentia and Rain Oncology. Please see the abstract for all other researchers’ relevant financial disclosures.
Greenberger reports no relevant financial disclosures.
Rau reports consulting/advisory roles with and/or honoraria from Jazz Pharmaceuticals and Servier. She also reports her spouse is employed by AbbVie. Please see the abstract for all other researchers’ relevant financial disclosures.
Zhang reports no relevant financial disclosures.
19 episodes
Share
